Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Tie1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Tie1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View Tie1 Products |
| Gene Delivery | Tie1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based activation assays. |
View Tie1 Products |
| Benchmark Ab | Anti-Tie1 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View Tie1 Products |
| Validator | Tie1 siRNA Set Target-specific knockdown pool for validation of functional specificity. |
View Tie1 Products |
| Related Target A | Tie2 (TEK) Coreceptor forming functional heterodimers with Tie1 to modulate angiopoietin signaling. |
View Tie2 Products |
| Related Target B | ANGPT2 (Angiopoietin-2) Antagonist/agonist ligand modulating the Tie1/Tie2 signaling axis during vascular remodeling. |
View ANGPT2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Evaluating Tie1/Tie2 Heterodimerization | High-purity, monomeric and dimeric (Fc-fusion) Tie1 and Tie2 proteins to support robust binding and co-immunoprecipitation assays. |
| Cross-Species Ortholog Reactivity | Human, Mouse, and Cynomolgus Tie1 recombinant proteins verified by SDS-PAGE and HPLC to ensure translational assay consistency. |
| Lack of Controls | Sequence-verified Clinical Benchmark Antibodies available as positive control references. |
| False Positives in Knockout Models | Sequence-verified siRNA pools included for precise target gene knockdown verification. |
Live Tie1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Tie1 (Tyrosine kinase with immunoglobulin-like and EGF-like domains 1) has emerged as a high-potential strategy for modulating vascular stability, tumor angiogenesis, and ocular neovascularization. Although historically classified as an orphan receptor, Tie1 is now recognized as a critical modulator of Tie2 signaling, acting as a molecular switch that sensitizes or desensitizes endothelial cells to Angiopoietin-1 and Angiopoietin-2.
The race for Tie1 therapeutics is intensifying, with major players shifting focus from traditional monospecific mAbs to bispecific antibodies and multi-targeted tyrosine kinase inhibitors (TKIs). As first-generation vascular therapies reach the clinic, the next wave of R&D is targeting the synergistic blockade of Tie1/Tie2 and VEGF pathways to address anti-VEGF resistance in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), as well as to restrict tumor metastasis by stabilizing tumor vasculature.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Regeneron, Roche, Academic Institutions | Oncology (Solid Tumors), Neovascular Eye Diseases | Epitope mapping & ligand-blocking validation (Requires high-purity Tie1 ECD-Fc) |
| Bispecific / Multi-specific Abs | Biotech Consortia, Eye-disease Specialists | Diabetic Retinopathy, Wet AMD, Oncology | Simultaneous binding assays (Requires active, native-conformation Tie1 and Tie2 proteins) |
| Small Molecule Inhibitors | Oncology-focused Pharma | Vascular Hyperpermeability, Metastatic Cancers | Kinase selectivity panels (Requires wild-type and mutant intracellular domain proteins) |